newsfilter
← Latest News
GlobeNewswire·

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering

ISELIN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today